FDA Approves Isembyld for SMA

Evidence Regulatory approval · Discovery September 11, 2026 · Importance 5/5 · Direction Positive Summary FDA approved Isembyld (apitegromab-mstn) for adults and children two years and older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment. The approval establishes the first U.S. therapy…